Company / Operating Income per Share
Viridian Therapeutics, Inc.\DE Operating Income per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$3.69
FY2024
5-year range
-$6.69 / -$3.69
FY2020-FY2024
Trend
+35.1%
vs FY2023
Sector context
#154 of 201
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's operating income per share of $-3.69 is lower than 77% of companies in the Health Care sector (FY2024). Operating Income per Share has fluctuated over the past 9 years, ranging from $-31.82 in FY2017 to $-1.12 in FY2018.
Based on SEC 10-K filings.
-3.69 in FY2024.
Improved from $-4.19 to $-3.69 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 201This company -$3.69 Sector average -$28.56
▼
+87.1% above sector average
Key checks
Key Insights
- In FY2024, operating income per share increased 35.1% year-over-year.
- Ranks #154 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2018.
- Lowest operating income per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$3.69 | +35.1% |
| FY2023 | -$5.69 | -35.8% |
| FY2022 | -$4.19 | +37.4% |
| FY2021 | -$6.69 | +78.4% |
| FY2020 | -$31.03 | -54.4% |
| FY2019 | -$20.09 | -1697.8% |
| FY2018 | -$1.12 | +96.5% |
| FY2017 | -$31.82 | -32.8% |
| FY2016 | -$23.96 | -710.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026